早期三阴性及HER2阳性乳腺癌治疗顺序框架的转变
本文讨论CREATE-X和KATHERINE试验的临床意义,指出新辅助化疗后残留病灶指导的术后卡培他滨或ado-trastuzumab emtansine治疗可改善无病生存,而先手术则丧失该机会。作者建议新辅助全身治疗应作为HER2阳性和雌激素受体阴性乳腺癌的新标准治疗,即使为可手术T1或T2病变。
要点
- 新辅助化疗可观察疗效并识别残留病灶高危患者。
- CREATE-X和KATHERINE支持残留病灶指导的术后辅助治疗。
- 先手术会丧失残留病灶指导治疗的机会。
核心结论
- 新辅助全身治疗应视为HER2阳性和雌激素受体阴性乳腺癌的新标准治疗,即使为可手术T1或T2病变。
研究设计与样本
- 本文为Personal View,讨论CREATE-X(UMIN000000843)和KATHERINE(NCT01772472)试验的临床意义。
主要发现
- 新辅助化疗后广泛残留浸润癌患者复发转移风险高,是临床试验的理想候选。
- CREATE-X和KATHERINE显示术后卡培他滨和ado-trastuzumab emtansine分别改善三阴性或HER2阳性乳腺癌新辅助化疗后残留病患者的无病生存。
关键数值与推荐
- CREATE-X和KATHERINE试验中,术后卡培他滨和ado-trastuzumab emtansine改善新辅助化疗后残留病患者的无病生存。
临床怎么用
- 对HER2阳性和雌激素受体阴性乳腺癌考虑新辅助全身治疗,即使可手术T1或T2病变。
- 新辅助化疗后残留病患者可接受残留病灶指导的术后辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Important results are emerging from clinical trials showing that surgery followed by chemotherapy might not be the optimal strategy to maximise a patient's chance of survival from triple-negative or HER2-positive breast cancers. Administering chemotherapy before surgery provides an opportunity to directly observe the efficacy of a particular chemotherapy regimen. Patients who have extensive residual invasive cancer after neoadjuvant chemotherapy are at a high risk of recurrence for metastatic disease, which, in turn, make these patients ideal candidates for clinical trials. Two important clinical trials, CREATE-X (UMIN000000843) and KATHERINE (NCT01772472), have shown improved disease-free survival with postoperative capecitabine and ado-trastuzumab emtansine in patients with either triple-negative or HER2-positive breast cancer who had residual disease after neoadjuvant chemotherapy. The opportunity for residual-disease guided therapy, as observed in these trials, is lost when patients undergo surgery first. In this Personal View, we discuss the clinical implications of the CREATE-X and KATHERINE trials and place them into context with other developments in the adjuvant setting of early-stage breast cancer. We suggest that neoadjuvant systemic therapy should be considered as the new standard of care for HER2-positive and oestrogen receptor negative breast cancer, even for patients who present with operable (T1 or T2) disease.
引用
- Pusztai L, Foldi J, Dhawan A, et al. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. Lancet Oncol. 2019. PMID: 31267973. doi:10.1016/S1470-2045(19)30158-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。